*Yondelis 0.25 mg and 1 mg powder for concentrate for solution for infusion.
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See SPC section 4.8 for how to report adverse reactions.